Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B, Chronic: Entecavir (NICE)
You must be a registered user to access the content and receive email bulletins from Healthcare Republic. If you have a paid subscription to MIMS or MIMS for Nurses, please activate your subscription. Otherwise, complete the free registration by choosing

Genelabs, NHRI collaborate on hepatitis C drug candidates
REDWOOD CITY, Calif.- has entered into a collaborative research agreement with the to discover and develop compounds that target the hepatitis C virus (HCV). HCV drug candidates will be developed using Genelabs' lead compounds on an existing target the

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

10-Year Follow-up After Interferon- Therapy for Chronic Hepatitis C

REFERENCES

1.Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767-770[ Medline].

2.Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362[ Medline].

3.Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell H, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B antibodies. Science 1989; 244: 362-364[ Medline].

4.Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, Rosenblatt J, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 335: 1-3[ Medline].

5.McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica, 1997:267-270.

6.Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. HEPATOLOGY 1997; 26(Suppl.): 15S-20S[ Medline].

7.Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. HEPATOLOGY 1997; 26(Suppl.): 34S-38S[ Medline].

8.Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. N Engl J Med 1986; 315: 1575-1578[ Medline].

9.Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510[ Medline].

10.Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506[ Medline].

11.Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, Coppere H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991; 13: 601-603[ Medline].

12.Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996; 24: 778-789[ Abstract].

13.Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. HEPATOLOGY 1992; 15: 1013-1016[ Medline].

14.Fong T-L, Shindo M, Feinstone SM, Hoofnagle JH, DiBisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991; 88: 1058-1060[ Medline].

15.National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. HEPATOLOGY 1997; 26(Suppl.): 2S-10S[ Medline].

16.Nolte FS, Thurmond C, Fried MV. Pre-clinical evaluation of Amplicor hepatitis C virus test for detection of hepatitis C virus RNA. J Clin Microbiol 1995; 33: 1775-1778[ Abstract].

17.Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. HEPATOLOGY 1997; 26: 1640-1645[ Abstract].

18.Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102[ Medline].

19.Simmonds P, Rose K, Graham S, Chan S-N, McOmish F, Dow B, Follett E, et al. Mapping of serotype-specific epitopes in the NS4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol 1993; 31: 1493-1503[ Abstract].

20.Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513-1520[ Medline].

21.Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdayin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903[ Medline].

22.Fong T-L, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. HEPATOLOGY 1993; 18: 1313-1318[ Medline].

23.Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow up of patients with chronic hepatitis C treated with different doses of interferon- 2b. HEPATOLOGY 1993; 18: 1300-1305[ Medline].

24.Shindo N, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon- therapy. Ann Intern Med 1995; 122: 586-591[ Medline].

25.Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon- therapy. Ann Intern Med 1997; 127: 875-881[ Medline].

26.Cammà C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxi A. Long-term course of interferon-treated chronic hepatitis C. J Hepatology 1998; 28: 531-537[ Medline].

27.Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of alfa-2b trials. HEPATOLOGY 1997; 26(Suppl.): 78S-82S[ Medline].

28.Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. HEPATOLOGY 1997; 26(Suppl.): 89S-95S[ Medline].

29.Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. HEPATOLOGY 1997; 26(Suppl.): 96S-100S[ Medline].

30.Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Heathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, the Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997; 26: 747-754[ Abstract].

31.Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997; 26(Suppl.): 21S-28S[ Medline].

32.Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466[ Medline].

0270-9139/98/2804-0030$3.00/0

Return To Article

table Of Contents

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 27 Aug 2008